Clinical trials
Pharmacokinetics and Pharmacodynamics clinical trials
Below are recruiting pharmacokinetics and pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 135 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06362343Recruiting
Personalized dosing study for Xa inhibitor blood thinners
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
Beijing, Beijing MunicipalityAges 18–120 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07798609RecruitingPhase 1/Phase 2
Testing SFL-0821 for people with FSHD
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
Concord, New South WalesAges 18–65 - NCT07738991RecruitingPhase 1
Study of NKF-PEG compared to Neulasta in healthy men
This study tests a new medicine called NKF-PEG, which is similar to Neulasta (a drug that helps boost white blood cells after chemotherapy). It is being tested in healthy men to see how the body processes it and to check for side effects.
ZhengzhouAges 18–55 - NCT07630714RecruitingPhase 2
Testing a new lupus medicine given under the skin in children
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
ParkvilleAges 5–17 - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT06715540RecruitingPhase 1
Study of a new drug for healthy male volunteers
This trial tests a new medicine called BCD-261 in healthy men to see if it is safe and how the body processes it. Participants will receive increasing doses and be monitored for about 4 months.
Saint PetersburgAges 18–45 - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT07494045RecruitingPhase 2
Study of CTAP101 for kids with chronic kidney disease
This study tests a new extended-release capsule (CTAP101) for children aged 8 to under 18 with moderate to severe chronic kidney disease (CKD). The goal is to see how the drug works in the body, if it's safe, and if it can help control mineral and hormone levels that are often out of balance in CKD.
Kansas City, MissouriAges 1 month–17 years - NCT06293651RecruitingPhase 1/Phase 2
Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
SeoulAges 18 years+ - NCT07384104Enrolling by invitationPhase 1
Comparing a new bone drug (SAL023) to Evenity in healthy volunteers
This trial tests a new medicine called SAL023 to see how it compares to an approved drug (Evenity) in healthy people. It looks at how the body processes the drug, safety, and immune response. You must be healthy, within a certain age and weight range, and not have any bone or heart problems.
Hefei, AnhuiAges 18–45 - NCT07358156RecruitingPhase 1
Comparing a new dupilumab medicine to Dupixent in healthy adults
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Berlin, State of BerlinAges 18–55 - NCT07334119RecruitingPhase 1
Testing MT-304 for advanced HER2-positive tumors
This trial tests a new drug, MT-304, for people with advanced cancers that have high levels of a protein called HER2. It aims to see if the drug is safe and helps shrink tumors.
Darlinghurst, New South WalesAges 18 years+ - NCT06869863RecruitingPhase 1/Phase 2
Study of MediReg® for severe male infertility
This study tests an experimental medicine called MediReg® for men with severe infertility who have not been able to conceive. It aims to see if the drug is safe and can improve sperm quality, possibly offering a new option for men who have not had success with other treatments.
Moscow, MoscowAges 21–60 - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT07303699RecruitingPhase 2
Atorvastatin with TB meds: a drug study for TB patients
This study tests if adding the cholesterol drug atorvastatin to standard TB treatment can help clear the infection faster. It looks at how the body processes the drugs and how well they work together.
Zaria, Kaduna StateAges 12 years+ - NCT07282574RecruitingPhase 2
Study of an add-on drug for progressive multiple sclerosis
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
Camperdown, New South WalesAges 18–60 - NCT07245771RecruitingPhase 1/Phase 2
Weight loss study testing a new drug alone or with tirzepatide
This trial tests an experimental drug called RN3161 to see if it helps with weight loss in people with overweight or obesity. It can be taken alone or with another weight-loss medication (tirzepatide).
Melbourne, VictoriaAges 18–65 - NCT07237464RecruitingPhase 1
Safety study of GB18 injection in healthy adults
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
Beijing, Beijing MunicipalityAges 18–55 - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07182552Enrolling by invitationPhase 1
Testing a new drug NTB003 in healthy volunteers
This early-phase trial tests the safety of a new drug called NTB003 in healthy people. It looks at how the drug moves through the body and affects it, which is a first step toward possibly treating certain conditions.
BeijingAges 25–45
Hear when a new Pharmacokinetics and Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacokinetics and pharmacodynamics?
- Yes. Clin2 currently lists 135 recruiting pharmacokinetics and pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacokinetics and pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacokinetics and pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.